Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1266800 | 1.00 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL164305 | 0.98 | TSHR (0.58) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL351072 | 0.98 | TSHR (0.58) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3613959 | 0.98 | TSHR (0.58) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL988663 | 0.98 | TSHR (0.58) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL44179 | 0.98 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL43894 | 0.95 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL44285 | 0.95 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL328732 | 0.95 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7971313 | 0.86 | TSHR (0.65) | TSHRLMNAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12864 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019150985-A1 | ANTIBODY-DRUG COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 国立大学法人東京大学 | 2019-08-08 | — | — | WO | claimed |
| WO-2011146568-A1 | PREDICTING RESPONSE TO A HER INHIBITOR | GENENTECH, INC. (US) | 2011-11-24 | — | — | WO | claimed |
| US-20080226659-A1 | Cancer treatment | IMMUNOGEN, INC. | 2008-09-18 | — | — | US | claimed |
| US-5401634-A | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-28 | — | — | US | claimed |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| US-20260144884-A1 | ANTI-LRRC15 ANTIBODY DRUG CONJUGATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144889-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION | SANOFI (FR) | 2026-05-28 | — | — | US | disclosed |
| US-20260144885-A1 | ANTI-LRRC15 ANTIBODIES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260144891-A1 | COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES | COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12637506-B2 | Fc-receptor binding modified asymmetric antibodies and methods of use | HOFFMANN-LA ROCHE INC. | 2026-05-26 | — | — | US | disclosed |
| US-20260137798-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-0279688-A2 | Methods and compositions for the use of HIV env polypeptides and antibodies thereto | GENENTECH, INC. (US) | 1988-08-24 | — | — | EP | disclosed |
| EP-0271918-A2 | Stable formulations of ricin toxin A chain and of RTA-immunoconjugates and stabilizer screening methods therefor | CETUS ONCOLOGY CORPORATION (US) | 1988-06-22 | — | — | EP | disclosed |
| EP-0269451-A2 | A new labelling design for a binding assay reagent | SCLAVO, INC. (US) | 1988-06-01 | — | — | EP | disclosed |
| WO-1988003412-A1 | SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS USING POLYPROLINE CONJUGATION | CETUS CORPORATION (US) | 1988-05-19 | — | — | WO | disclosed |
| EP-0257758-A2 | Stable biologically active fluorochemical emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0256714-A2 | Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2 | CETUS ONCOLOGY CORPORATION (US) | 1988-02-24 | — | — | EP | disclosed |
| WO-1985003523-A1 | MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES | CETUS CORPORATION (US) | 1985-08-15 | — | — | WO | disclosed |
| WO-1985003508-A1 | TOXIN CONJUGATES | CETUS CORPORATION (US) | 1985-08-15 | — | — | WO | disclosed |